Ganaxolone - PubMed (original) (raw)

Review

Ganaxolone

Virinder Nohria et al. Neurotherapeutics. 2007 Jan.

Abstract

Ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) (GNX) is the 3beta-methylated synthetic analog of allopregnanolone; it belongs to a class of compounds referred to as neurosteroids. GNX is an allosteric modulator of GABA(A) receptors acting through binding sites which are distinct from the benzodiazepine binding site. It has activity in a broad range of animal models of epilepsy. GNX has been shown to be well tolerated in adults and children. In early phase II studies, GNX has been shown to have activity in adult patients with partial-onset seizures and epileptic children with history of infantile spasms. It is currently undergoing further development in infants with newly diagnosed infantile spasms, in women with catamenial epilepsy, and in adults with refractory partial-onset seizures.

PubMed Disclaimer

Similar articles

• Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy.
  Reddy DS, Rogawski MA. Reddy DS, et al. J Pharmacol Exp Ther. 2000 Sep;294(3):909-15. J Pharmacol Exp Ther. 2000. PMID: 10945840
• Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.
  Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, Gee KW. Carter RB, et al. J Pharmacol Exp Ther. 1997 Mar;280(3):1284-95. J Pharmacol Exp Ther. 1997. PMID: 9067315
• Pharmacology of catamenial epilepsy.
  Reddy DS. Reddy DS. Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):547-61. doi: 10.1358/mf.2004.26.7.863737. Methods Find Exp Clin Pharmacol. 2004. PMID: 15538544 Review.
• Anti-apoptotic Actions of Allopregnanolone and Ganaxolone Mediated Through Membrane Progesterone Receptors (PAQRs) in Neuronal Cells.
  Thomas P, Pang Y. Thomas P, et al. Front Endocrinol (Lausanne). 2020 Jun 24;11:417. doi: 10.3389/fendo.2020.00417. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32670200 Free PMC article. Review.

Cited by

• Neurosteroids and epilepsy.
  Biagini G, Panuccio G, Avoli M. Biagini G, et al. Curr Opin Neurol. 2010 Apr;23(2):170-6. doi: 10.1097/WCO.0b013e32833735cf. Curr Opin Neurol. 2010. PMID: 20160650 Free PMC article. Review.
• Insights into GABAAergic system alteration in Huntington's disease.
  Hsu YT, Chang YG, Chern Y. Hsu YT, et al. Open Biol. 2018 Dec 5;8(12):180165. doi: 10.1098/rsob.180165. Open Biol. 2018. PMID: 30518638 Free PMC article. Review.
• Modifications of antiepileptic drugs for improved tolerability and efficacy.
  Landmark CJ, Johannessen SI. Landmark CJ, et al. Perspect Medicin Chem. 2008 Feb 14;2:21-39. Perspect Medicin Chem. 2008. PMID: 19787095 Free PMC article.
• Neurosteroid replacement therapy for catamenial epilepsy.
  Reddy DS, Rogawski MA. Reddy DS, et al. Neurotherapeutics. 2009 Apr;6(2):392-401. doi: 10.1016/j.nurt.2009.01.006. Neurotherapeutics. 2009. PMID: 19332335 Free PMC article. Review.
• Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
  Olson HE, Daniels CI, Haviland I, Swanson LC, Greene CA, Denny AMM, Demarest ST, Pestana-Knight E, Zhang X, Moosa AN, Fidell A, Weisenberg JL, Suter B, Fu C, Neul JL, Percy AK, Marsh ED, Benke TA, Poduri A. Olson HE, et al. J Neurodev Disord. 2021 Sep 16;13(1):40. doi: 10.1186/s11689-021-09384-z. J Neurodev Disord. 2021. PMID: 34530725 Free PMC article.

References

1. 1. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABAA receptor. Nat Rev Neurosci. 2005;6:565–575. doi: 10.1038/nrn1703. - DOI - PubMed
2. 1. Akk G, Bracamontes JR, Covey DF, Evers A, Dao T, Steinbach JH. Neuroactive steroids have multiple actions to potentiate GABAA receptors. J Physiol. 2004;558:59–74. doi: 10.1113/jphysiol.2004.066571. - DOI - PMC - PubMed
3. 1. Rogawski MA, Reddy DS. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho JM, Sankar R, Cavazos JE, editors. Epilepsy: scientific foundations of clinical practice. New York: Marcel Dekker; 2004. pp. 319–355.
4. 1. Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acidA receptor. J Pharmacol Exp Ther. 1997;280:1284–1295. - PubMed
5. 1. Liptakova S, Velisek L, Veliskova J, Moshe SL. Effect of ganaxolone on flurothyl seizures in developing rats. Epilepsia. 2000;41:788–793. doi: 10.1111/j.1528-1157.2000.tb00244.x. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information